Huber P R, Mattarelli G, Strittmatter B, van Steenbrugge G J, Schmid H P, Maurer A
Hormone Laboratory DZL, Kantonsspital Basel, Roche Diagnostic Systems, F. Hoffmann-La Roche Ltd., Switzerland.
Prostate. 1995 Sep;27(3):166-75. doi: 10.1002/pros.2990270308.
Complex formation of prostate specific antigen (PSA) with its inhibitor alpha 1-anti-chymotrypsin (ACT) in vivo and in vitro was studied. Patients with benign prostatic hyperplasia (BPH) were treated with the computer assisted device "Prostatron." This instrument acts by means of thermal destruction of prostatic tissue. The effect of the treatment was followed by measurement of serum PSA concentrations using commercially available immunoassays from Roche (Cobas Core), Wallac (Delfia) and Abbot (IMx) and Hybritech Tandem. Serum samples were further analyzed by molecular sieving on S.300 (Pharmacia) and analyzed for PSA by immuno assay. The complex formation of PSA with ACT in serum was studied, demonstrating this process to be influenced by external stimulus. Patient sera revealing initially normal PSA levels (3 to 5 ng/ml) were stimulated to very high levels of PSA (> or = 140 ng/ml) by Prostatron treatment. The absolute PSA level depends on the assay system and not only on the staging of the prostate tumor. In addition, complex formation was studied in athymic nude mice and in vitro revealing the possible pathways of PSA release. PSA from LNCAP cells kept in vitro show predominantly uncomplexed (free) PSA, whereas PSA from LNCAP cells injected into nude mice appears in the serum of the animals in complexed form. This demonstrates how in the immunization process free and complexed PSA serve as antigens in the standard procedure for the production of antisera for PSA. This model system also can be used for studies of the release mechanism of PSA into blood circulation.
研究了前列腺特异性抗原(PSA)与其抑制剂α1-抗糜蛋白酶(ACT)在体内和体外的复合物形成。对良性前列腺增生(BPH)患者使用计算机辅助设备“前列腺治疗仪(Prostatron)”进行治疗。该仪器通过热破坏前列腺组织发挥作用。治疗效果通过使用罗氏公司(Cobas Core)、瓦里安公司(Delfia)、雅培公司(IMx)的市售免疫测定法以及Hybritech Tandem测定血清PSA浓度来跟踪。血清样本进一步通过S.300(Pharmacia)进行分子筛分,并通过免疫测定法分析PSA。研究了血清中PSA与ACT的复合物形成,表明该过程受外部刺激影响。最初PSA水平正常(3至5 ng/ml)的患者血清经前列腺治疗仪治疗后被刺激到非常高的PSA水平(≥140 ng/ml)。PSA的绝对水平取决于测定系统,而不仅取决于前列腺肿瘤的分期。此外,在无胸腺裸鼠体内和体外研究了复合物形成,揭示了PSA释放的可能途径。体外培养的LNCAP细胞产生的PSA主要以未复合(游离)形式存在,而注射到裸鼠体内的LNCAP细胞产生的PSA则以复合形式出现在动物血清中。这证明了在免疫过程中游离和复合的PSA如何在生产PSA抗血清的标准程序中作为抗原。该模型系统也可用于研究PSA释放到血液循环中的机制。